EHI
Eagle Health Investments Portfolio holdings
AUM
$405M
This Quarter Return
-0.71%
1 Year Return
+14.19%
3 Year Return
+134.25%
5 Year Return
–
10 Year Return
–
AUM
$408M
AUM Growth
+$408M
(-21%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-25.76%
Top 10 Holdings %
Top 10 Hldgs %
85.04%
Holding
25
New
–
Increased
3
Reduced
5
Closed
6
Top Buys
| 1 |
Icon
ICLR
|
$16.4M |
| 2 |
Neurocrine Biosciences
NBIX
|
$3.6M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$2.77M |
Top Sells
| 1 |
Exact Sciences
EXAS
|
$37.1M |
| 2 |
UnitedHealth
UNH
|
$29.6M |
| 3 |
Natera
NTRA
|
$14.5M |
| 4 |
DexCom
DXCM
|
$13.8M |
| 5 |
United Therapeutics
UTHR
|
$11.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$23.1B
| $53.8M | 13.19% |
339,764
-91,550
| -21% | -$14.5M |
|
2
argenx
ARGX
$43.6B
| $46.1M | 11.31% |
74,990
| – | – |
|
3
Illumina
ILMN
$15.8B
| $45.9M | 11.25% |
343,361
-43,993
| -11% | -$5.88M |
|
|
4
Icon
ICLR
$13.8B
| $43.9M | 10.75% |
209,190
+78,400
| +60% | +$16.4M |
|
5
Insmed
INSM
$28.8B
| $35.5M | 8.69% |
513,700
| – | – |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $27.6M | 6.76% |
419,212
| – | – |
|
|
7
Ultragenyx Pharmaceutical
RARE
$2.89B
| $26.4M | 6.47% |
627,600
+65,900
| +12% | +$2.77M |
|
8
Inspire Medical Systems
INSP
$2.77B
| $25.3M | 6.21% |
136,603
| – | – |
|
|
9
DexCom
DXCM
$29.5B
| $21.4M | 5.23% |
274,551
-176,941
| -39% | -$13.8M |
|
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $21.2M | 5.19% |
155,000
+26,400
| +21% | +$3.6M |
|
11
Procept Biorobotics
PRCT
$2.23B
| $18.8M | 4.6% |
233,089
| – | – |
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $17.9M | 4.4% |
76,256
| – | – |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $10.9M | 2.67% |
330,830
| – | – |
|
|
14
United Therapeutics
UTHR
$13.8B
| $7.69M | 1.89% |
21,802
-32,297
| -60% | -$11.4M |
|
15
Intuitive Surgical
ISRG
$170B
| $2.29M | 0.56% |
4,390
-3,000
| -41% | -$1.57M |
|
16
Immunocore
IMCR
$1.62B
| $1.37M | 0.33% |
46,300
| – | – |
|
17
Transmedics
TMDX
$3.92B
| $1.13M | 0.28% |
18,061
| – | – |
|
|
GRAL
18
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $948K | 0.23% |
53,124
| – | – |
|
19
CRISPR Therapeutics
CRSP
$4.71B
| – | – |
0
| – | – |
|
|
20
Exact Sciences
EXAS
$8.98B
| – | – |
-544,200
| Closed | -$37.1M |
|
21
4D Molecular Therapeutics
FDMT
$288M
| – | – |
-462,911
| Closed | -$5M |
|
22
Werewolf Therapeutics
HOWL
$59.9M
| – | – |
-700,000
| Closed | -$1.48M |
|
23
Lantheus
LNTH
$3.73B
| – | – |
-43,200
| Closed | -$4.74M |
|
|
24
UnitedHealth
UNH
$281B
| – | – |
-50,700
| Closed | -$29.6M |
|
25
Viking Therapeutics
VKTX
$3.04B
| – | – |
-45,000
| Closed | -$2.85M |
|